Sumitomo Mitsui Trust Holdings Inc. Sells 32,130 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Sumitomo Mitsui Trust Holdings Inc. lowered its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 0.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,551,313 shares of the company’s stock after selling 32,130 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 6.14% of Twist Bioscience worth $121,846,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. D.A. Davidson & CO. lifted its holdings in Twist Bioscience by 3.4% during the fourth quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after purchasing an additional 554 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience during the 4th quarter valued at approximately $30,000. Federated Hermes Inc. bought a new position in Twist Bioscience in the 3rd quarter worth approximately $29,000. Franklin Resources Inc. grew its stake in Twist Bioscience by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 173,924 shares of the company’s stock valued at $6,411,000 after buying an additional 2,263 shares in the last quarter. Finally, International Assets Investment Management LLC raised its holdings in Twist Bioscience by 3,519.8% during the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after acquiring an additional 3,907 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of several recent research reports. Barclays lifted their price target on Twist Bioscience from $45.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, June 28th. Robert W. Baird upped their price target on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. TD Cowen raised their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Evercore ISI upped their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Finally, Scotiabank raised their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Buy” and an average price target of $48.50.

Twist Bioscience Trading Up 1.4 %

Shares of Twist Bioscience stock opened at $48.00 on Thursday. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $55.26. The company has a 50 day simple moving average of $44.89 and a two-hundred day simple moving average of $38.64.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. The company had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm’s revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.06) EPS. As a group, equities research analysts expect that Twist Bioscience Co. will post -3.08 EPS for the current year.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 910 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $33,788.30. Following the completion of the sale, the senior vice president now owns 91,511 shares in the company, valued at approximately $3,397,803.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider William Banyai sold 798 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $29,629.74. Following the transaction, the insider now owns 345,188 shares of the company’s stock, valued at approximately $12,816,830.44. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Paula Green sold 910 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $33,788.30. Following the completion of the sale, the senior vice president now directly owns 91,511 shares of the company’s stock, valued at $3,397,803.43. The disclosure for this sale can be found here. In the last three months, insiders sold 17,246 shares of company stock worth $706,593. 3.92% of the stock is currently owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.